Arcoma Yönetim

Yönetim kriter kontrolleri 2/4

Arcoma CEO'su Mattias Leire, Feb2023 tarihinde atandı, in görev süresi 3.25 yıldır. şirketin hisselerinin 1.03% doğrudan sahiptir ve bu hisselerin değeri SEK 1.39M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 9.3 yıldır.

Anahtar bilgiler

Mattias Leire

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.3yrs
CEO sahipliği	1.0%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	9.3yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Oct 30

Investors Aren't Entirely Convinced By Arcoma AB's (STO:ARCOMA) Earnings

With a price-to-earnings (or "P/E") ratio of 18.8x Arcoma AB ( STO:ARCOMA ) may be sending bullish signals at the...

Analiz Makalesi • Aug 24

Arcoma AB (STO:ARCOMA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Last week, you might have seen that Arcoma AB ( STO:ARCOMA ) released its second-quarter result to the market. The...

Analiz Makalesi • Jul 09

Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

The Arcoma AB ( STO:ARCOMA ) share price has done very well over the last month, posting an excellent gain of 25...

Analiz Makalesi • Jan 15

Is Arcoma (STO:ARCOMA) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analiz Makalesi • Sep 11

We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Analiz Makalesi • Jun 08

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Analiz Makalesi • Apr 27

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Arcoma AB ( STO:ARCOMA ), is not the largest company out there, but it led the OM gainers with a relatively large price...

Analiz Makalesi • Dec 22

Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Analiz Makalesi • May 03

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analiz Makalesi • Oct 28

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analiz Makalesi • Mar 17

Is Arcoma (STO:ARCOMA) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Analiz Makalesi • Feb 04

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

While Arcoma AB ( STO:ARCOMA ) might not be the most widely known stock at the moment, it received a lot of attention...

Analiz Makalesi • Jan 14

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

We note that a Arcoma AB ( STO:ARCOMA ) insider, Johan Henningsson, recently sold kr390k worth of stock for kr25.18 per...

Analiz Makalesi • Jan 12

Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Arcoma (STO:ARCOMA) has had a great run on the share market with its stock up by a significant 31% over the last three...

Analiz Makalesi • Dec 17

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analiz Makalesi • Nov 21

Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Does the November share price for Arcoma AB (STO:ARCOMA) reflect what it's really worth? Today, we will estimate the...

CEO

Mattias Leire (44 yo)

3.3yrs

Görev süresi

Mr. Mattias Leire is Chief Executive Officer of Arcoma AB from February 2023. He joined the Arcoma AB in 2023. He has extensive experience from leading positions, including many years within Atos Medical....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mattias Leire	Chief Executive Officer	3.3yrs	Veri yok	1.03% SEK 1.4m
Johan Dahlberg	Chief Financial Officer	4yrs	Veri yok	0.021% SEK 28.1k
Andre Malmberg	Chief Operating Officer	1.3yrs	Veri yok	Veri yok
Daniel Warawasowski	Global Sales Director	2.3yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

42yo

Ortalama Yaş

Deneyimli Yönetim: ARCOMA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jan Wahlstrom	Independent Director	4yrs	SEK 100.00k	0.49% SEK 656.6k
Mats Thoren	Director	16.3yrs	SEK 100.00k	4.67% SEK 6.3m
Lars Kvarnhem	Chairman	9.3yrs	SEK 400.00k	Veri yok

9.3yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ARCOMA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/22 05:50
Gün Sonu Hisse Fiyatı	2026/05/22 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Arcoma AB 1 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Hjalmar Jernstrom	DNB Carnegie Commissioned Research

Arcoma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Arcoma AB, Annual General Meeting, May 20, 2026

Arcoma AB, Annual General Meeting, May 14, 2025

Less than half of directors are independent

No independent directors

Director recently bought kr119k worth of stock

Arcoma AB, Annual General Meeting, May 25, 2021

Recent updates

Investor sentiment improves as stock rises 17%

Price target decreased by 16% to kr9.50

First quarter 2026 earnings released: EPS: kr0.057 (vs kr0.15 in 1Q 2025)

New minor risk - Share price stability

Arcoma AB, Annual General Meeting, May 20, 2026

Arcoma AB to Report Q1, 2026 Results on Apr 23, 2026

New minor risk - Profit margin trend

Consensus EPS estimates fall by 24%

Arcoma AB to Report Fiscal Year 2025 Results on Apr 09, 2026

Investors Aren't Entirely Convinced By Arcoma AB's (STO:ARCOMA) Earnings

New minor risk - Profit margin trend

Consensus EPS estimates fall by 17%

Arcoma AB (STO:ARCOMA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Second quarter 2025 earnings released: EPS: kr0 (vs kr0.28 in 2Q 2024)

Consensus EPS estimates fall by 14%

Arcoma AB (STO:ARCOMA) Looks Inexpensive But Perhaps Not Attractive Enough

Price target decreased by 18% to kr12.50

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Arcoma AB, Annual General Meeting, May 14, 2025

Full year 2024 earnings: EPS and revenues miss analyst expectations

Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop

Price target increased by 13% to kr17.00

Investor sentiment deteriorates as stock falls 16%

Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business

Second quarter 2024 earnings released: EPS: kr0.28 (vs kr0.031 in 2Q 2023)

At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

First quarter 2024 earnings released: EPS: kr0.34 (vs kr0.18 loss in 1Q 2023)

Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Arcoma AB to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment improves as stock rises 17%

Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

New major risk - Market cap size

Is Arcoma (STO:ARCOMA) A Risky Investment?

Third quarter 2023 earnings released: EPS: kr0.15 (vs kr0.11 in 3Q 2022)

We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings released: EPS: kr0.031 (vs kr0.11 in 2Q 2022)

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

First quarter 2023 earnings released: kr0.18 loss per share (vs kr0.093 loss in 1Q 2022)

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Full year 2022 earnings released: EPS: kr0.14 (vs kr0.58 loss in FY 2021)

Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr0.11 (vs kr0.24 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: kr0.11 (vs kr0.079 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Price target decreased to kr16.50

No independent directors

Director recently bought kr119k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr21.00

Third quarter 2021 earnings released: kr0.24 loss per share (vs kr0.082 profit in 3Q 2020)

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Second quarter 2021 earnings released: EPS kr0.079 (vs kr0.18 in 2Q 2020)

First quarter 2021 earnings released: EPS kr0.15 (vs kr0.31 in 1Q 2020)

Is Arcoma (STO:ARCOMA) A Risky Investment?

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS kr0.12 (vs kr0.52 in FY 2019)

Arcoma AB, Annual General Meeting, May 25, 2021

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Insider recently sold kr390k worth of stock

Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Investor sentiment improved over the past week

New 90-day high: kr21.90

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Arcoma AB Launches Omnera 500A

Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)